8,3 %HIV prevalence among tertiary student MSM in Nairobi was 8.3%.
KenyaVIH/sidaobservé 2021publié 2023AIDS research and therapyPubMeddocument de 14 observations
Palier Gold : evidences validées mécaniquement, avec leur source primaire.
2 235 evidences · page 53 / 90
8,3 %HIV prevalence among tertiary student MSM in Nairobi was 8.3%.
KenyaVIH/sidaobservé 2021publié 2023AIDS research and therapyPubMeddocument de 14 observations
37,5 %37.5% of adolescent girls were unaware if their partner had ever tested for HIV.
KenyaVIH/sidapublié 2023The Journal of adolescent health : official publication of the Society for Adolescent MediPubMeddocument de 7 observations
15 %Pneumocystis jirovecii was present in 24 (15%) of 162 HIV-attributed infant or child deaths.
KenyaVIH/sidaobservé Dec 3, 2016 to Dec 31, 2024publié 2026The lancet. HIVPubMeddocument de 23 observations
0,8 %The percentage of HIV infections with PrEP-associated nucleoside reverse transcriptase inhibitor (NRTI) drug resistance was 0.8% in the oral HIV self-testing scenario.
KenyaVIH/sidapublié 2024The lancet. HIVPubMeddocument de 6 observations
78 %Missed opportunities in screening for PrEP eligibility were 78% for adolescent girls and young women (AGYW).
KenyaVIH/sidaobservé February 2017 to December 2019publié 2020Journal of the International AIDS SocietyPubMeddocument de 13 observations
0,8 %The proportion of infants diagnosed with HIV was 0.8% in the intervention group.
KenyaVIH/sidapublié 2021Scientific reportsPubMeddocument de 4 observations
82 000 childrenIn Kenya, of the 82,000 children living with HIV, only 59% are receiving antiretroviral therapy (ART).
KenyaVIH/sidapublié 2024Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 8 observations
3,65 AORFemale participants had nearly four-fold higher odds of water insecurity (adjusted odds ratio = 3.65).
KenyaVIH/sidapublié 2026Journal of water and healtheurope_pmcdocument de 11 observations
38,9 %Among 31,346 patients initiated on antiretroviral therapy in central Kenya, 38.9% were diagnosed at WHO stage III.
KenyaVIH/sidapublié 2022BMC infectious diseasesPubMeddocument de 10 observations
96,6 %Protease (PR) and reverse transcriptase (RT) sequences of plasma viral RNA were obtained for 96.6% and 89.7%, respectively, of the 29 patients with a detectable viral load.
KenyaVIH/sidapublié 2007Journal of clinical microbiologyeurope_pmcdocument de 4 observations
59 %After 19 months of follow-up, 44 out of 75 participants living with HIV (59%) were virally suppressed at their last viral load measure.
KenyaVIH/sidapublié 2023BMC health services researchPubMeddocument de 12 observations
21,32 USD_per_person_per_monthThe average economic cost of PrEP provision was $21.32 per person per month.
KenyaVIH/sidaobservé first year of programmatic PrEP deliverypublié 2021BMC health services researchPubMeddocument de 4 observations
1,6 per_100_person_yearsMortality rate was 1.6 per 100 person-years.
KenyaVIH/sidapublié 2022International journal of environmental research and public healthPubMeddocument de 5 observations
71,2 %Among 305 inpatients, 71.2% in the Democratic Republic of Congo had viral load ≥1000 copies/mL.
KenyaVIH/sidapublié 2021Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 14 observations
19 %Among 423 HIV-negative Kenyan men who have sex with men and transgender women, yearly implant was preferred by 19% in pairwise comparisons.
KenyaVIH/sidapublié 2023AIDS and behaviorPubMeddocument de 9 observations
4,7 %Among women accepting HIV self-testing in the PrEP Implementation of Mothers in Antenatal Care trial in Kenya, awareness of partner HIV status increased from 4.7% to 82.0% between pregnancy and 9 months postpartum.
KenyaVIH/sidaobservé pregnancy to 9 months postpartumpublié 2024Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 11 observations
22,9 %Cumulative lost to follow-up incidence among children and adolescents initiating antiretroviral therapy in central Kenya was 22.9% at 24 months.
KenyaVIH/sidapublié 2022AIDS research and human retrovirusesPubMeddocument de 18 observations
5,1 %At week 48, 5.1% of participants in the ritonavir-boosted PI group met the primary end point of plasma HIV type 1 RNA level of at least 50 copies per milliliter.
KenyaVIH/sidaobservé week 48publié 2023The New England journal of medicinePubMeddocument de 8 observations
67 %Among ART-experienced persons with baseline viremia, viral suppression at year 3 was 67% in the intervention arm and 47% in the control arm.
KenyaVIH/sidapublié 2020Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 4 observations
2,08 aHRDepot medroxyprogesterone acetate (DMPA) was significantly associated with elevated risk of HIV seroconversion in women without bacterial vaginosis (adjusted hazard ratio 2.08, 95% confidence interval 1.46–2.97).
Kenyavaginose bactérienne · VIH/sidaobservé 1993 to 2017publié 2019AIDS (London, England)europe_pmcdocument de 4 observationsDOI 10.1097/qad.0000000000002167
99 %For AGYW engaged in sex work, awareness of local HIV prevention programmes was associated with at least one HIV test (99%).
KenyaVIH/sidapublié 2020Sexual and reproductive health mattersPubMeddocument de 8 observations
23,2 %The prevalence of hypertension was found to be 23.2% among HIV positive adult patients at Kenyatta National Hospital HIV Care Centre.
Kenyahypertension artérielle · VIH/sidaobservé 2015publié 2018AIDS careeurope_pmcdocument de 4 observations
1,84 adjusted_risk_ratioDrug resistance penalty score (DR-PS) ≥ 30 was associated with age 1–5 years (adjusted risk ratio = 1.84).
KenyaVIH/sidaobservé 2019 to 2023publié 2025VirusesPubMeddocument de 8 observations
90,7 %Standard care resulted in 90.7% of persons living with HIV (PLWH) knowing their status.
KenyaVIH/sidapublié 2022Journal of acquired immune deficiency syndromes (1999)PubMeddocument de 9 observations
96 %Among the 1178 clients reached for follow-up, 96% (1136/1178) tested HIV-negative at the pharmacy.
KenyaVIH/sidaobservé March to June 2022publié 2025BMC health services researchPubMeddocument de 13 observations
Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.